Figure 6.

Non-invasive fast drug screening of doxorubicin (DOX) in Apo-S-Ac₃ManNAz-treated PC-3 tumor-bearing mice (n = 5). (a) In vitro CLSM images of PC-3 tumor cells treated with different concentrations of DOX (0, 1, 3, 5, 10 and 20 μM) for 24 h. (b) FACS analysis of DOX-treated PC-3 tumor cells, wherein the apoptotic tumor cells were monitored using Annexin V-FITC staining. (c) In vivo non-invasive bioorthogonal apoptosis imaging of PC-3 tumor tissues after direct injection of DOX (0, 1, 3, 5 mg/kg) to PC-3 tumor-bearing mice. After 2 day post-injection of DOX, the apoptosis-induced azido groups were monitored with the I.V. injection of DBCO-Cy5.5 (4 mg/kg) and the NIRF intensity in each tumor tissue was quantitatively monitored using IVIS imaging system. (d) Ex vivo NIRF image of DOX-treated PC-3 tumor tissues (DOX’s concentration = 0, 1, 3, 5 mg/kg). (e) NIRF intensity of PC-3 tumor tissues (n = 5) was quantified by Living Image software. (f) CLSM images of PC-3 tumor tissues from the excised tumor tissues (d). (Red = DBCO-Cy5.5 channel; Green = Annexin V-FITC channel; Blue = DAPI channel).